Biotech-focused investment firm The Column Group has passed the halfway mark for its $250m-targeting second venture capital fund, according to documents filed with US securities regulators.
Column Group II has raised $175.85m from 28 LPs, which were asked to commit at least $100,000, the filing showed.
The San Francisco-based firm is raising the fund without a placement agent and registered the first commitment earlier this month.
Column closed its debut vehicle on $65.5m in March 2010.
The firm aims to invest in 10 to 12 disease-focused drug discovery companies per fund, committing between $15m and $30m per deal.
Its portfolio businesses include vaccine company Immune Design, orally administered small-molecule drugs developer PTC and Constellation, which is focused on epigenetics, a new field of science involving selective regulators that are critical to controlling gene expression.
Copyright © 2014 AltAssets